Angiotensin-induced hypertension chemotherapy in children with advanced solid tumors

Acta Paediatr Jpn. 1991 Jun;33(3):381-3. doi: 10.1111/j.1442-200x.1991.tb01570.x.

Abstract

Angiotensin-induced hypertension chemotherapy (IHC) was investigated in six children with the following advanced malignancies: hepatocellular carcinoma, extraskeletal Ewing's sarcoma, sacrococcygeal malignant teratoma, small round cell tumor of the chest wall, hepatoblastoma and osteogenic sarcoma. Partial response was achieved in three of these patients, two showed no change, and in one IHC was used as adjuvant chemotherapy. The side effects of IHC were minimal and tolerable. Angiotensin-IHC may provide a new approach to pediatric cancer chemotherapy.

MeSH terms

  • Adolescent
  • Angiotensin II / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / blood supply
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / pathology
  • Carcinoma, Hepatocellular / blood supply
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / pathology
  • Child
  • Child, Preschool
  • Coccyx
  • Female
  • Humans
  • Hypertension / chemically induced*
  • Infant
  • Infusions, Intravenous
  • Liver Neoplasms / blood supply
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / pathology
  • Lung Neoplasms / blood supply
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / etiology
  • Lung Neoplasms / secondary
  • Male
  • Neoplasm Staging
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Sacrum
  • Thoracic Neoplasms / drug therapy

Substances

  • Angiotensin II